Literature DB >> 14631580

[Diabetic complications. Micro and macroangiopathic end-organ damage].

U D Lichtenauer1, J Seissler, W A Scherbaum.   

Abstract

Diabetes-associated sequelae lead to a considerable reduction in the quality of life and conspicuous increase in mortality. Subsequent damage becomes manifest in terms of macroangiopathy as coronary heart disease, peripheral arterial occlusive disease, and cerebrovascular insufficiency. Moreover, there is high risk of diabetic nephropathy, neuropathy, and retinopathy entailing the danger of developing chronic renal failure, loss of vision, or diabetic foot syndrome. Although chronic hyperglycemia constitutes a separate risk factor for macro- and microangiopathic complications, associated disorders such as arterial hypertension and hypercholesterinemia increase the mortality risk to a significant extent. Hence, in the past few years, new concepts have been developed for improving the diagnosis, therapy, and long-term care of people with diabetes to include diligent treatment of concomitant risk factors in addition to maintaining near-normal blood glucose levels. This optimized medical care can improve the quality of life and prognosis of patients with diabetes mellitus.

Entities:  

Mesh:

Year:  2003        PMID: 14631580     DOI: 10.1007/s00108-003-0996-3

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  64 in total

1.  Effects of 3-week oral treatment with the antioxidant thioctic acid (alpha-lipoic acid) in symptomatic diabetic polyneuropathy.

Authors:  K J Ruhnau; H P Meissner; J R Finn; M Reljanovic; M Lobisch; K Schütte; D Nehrdich; H J Tritschler; H Mehnert; D Ziegler
Journal:  Diabet Med       Date:  1999-12       Impact factor: 4.359

2.  Autonomic neuropathy and prolongation of QT-interval in liver disease.

Authors:  P Kempler; A Váradi; F Szalay
Journal:  Lancet       Date:  1992-08-01       Impact factor: 79.321

Review 3.  Diabetic neuropathies.

Authors:  A A Sima; P K Thomas; D Ishii; A Vinik
Journal:  Diabetologia       Date:  1997-10       Impact factor: 10.122

4.  [Causes of blindness in Hessia in 1996].

Authors:  M Gräf; E Halbach; H Kaufmann
Journal:  Klin Monbl Augenheilkd       Date:  1999-07       Impact factor: 0.700

5.  The effect of diabetes mellitus on prognosis and serial left ventricular function after acute myocardial infarction: contribution of both coronary disease and diastolic left ventricular dysfunction to the adverse prognosis. The MILIS Study Group.

Authors:  P H Stone; J E Muller; T Hartwell; B J York; J D Rutherford; C B Parker; Z G Turi; H W Strauss; J T Willerson; T Robertson
Journal:  J Am Coll Cardiol       Date:  1989-07       Impact factor: 24.094

6.  Familial factors determine the development of diabetic nephropathy in patients with IDDM.

Authors:  M Quinn; M C Angelico; J H Warram; A S Krolewski
Journal:  Diabetologia       Date:  1996-08       Impact factor: 10.122

7.  Advanced glycation endproducts promote adhesion molecule (VCAM-1, ICAM-1) expression and atheroma formation in normal rabbits.

Authors:  H Vlassara; H Fuh; T Donnelly; M Cybulsky
Journal:  Mol Med       Date:  1995-05       Impact factor: 6.354

8.  Predicting diabetic nephropathy in insulin-dependent patients.

Authors:  C E Mogensen; C K Christensen
Journal:  N Engl J Med       Date:  1984-07-12       Impact factor: 91.245

9.  Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study.

Authors:  Y Ohkubo; H Kishikawa; E Araki; T Miyata; S Isami; S Motoyoshi; Y Kojima; N Furuyoshi; M Shichiri
Journal:  Diabetes Res Clin Pract       Date:  1995-05       Impact factor: 5.602

10.  Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy.

Authors:  Y Harati; C Gooch; M Swenson; S Edelman; D Greene; P Raskin; P Donofrio; D Cornblath; R Sachdeo; C O Siu; M Kamin
Journal:  Neurology       Date:  1998-06       Impact factor: 9.910

View more
  2 in total

1.  Precision medicine approach: Empagliflozin for diabetic cardiomyopathy in mice with aldehyde dehydrogenase (ALDH) 2 * 2 mutation, a specific genetic mutation in millions of East Asians.

Authors:  Guodong Pan; Mandar Deshpande; Haiyan Pang; Suresh Selvaraj Palaniyandi
Journal:  Eur J Pharmacol       Date:  2018-09-19       Impact factor: 5.195

2.  Comparison of the effects of remifentanil-based general anesthesia and popliteal nerve block on postoperative pain and hemodynamic stability in diabetic patients undergoing distal foot amputation: A retrospective observational study.

Authors:  Na Young Kim; Ki-Young Lee; Sun Joon Bai; Jung Hwa Hong; Jinwoo Lee; Jong Min Park; Shin Hyung Kim
Journal:  Medicine (Baltimore)       Date:  2016-07       Impact factor: 1.889

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.